Holen Sie sich die Stockscreener-App
13.06
2.40%
-0.3374
Schlusskurs vom Vortag:
$13.40
Offen:
$13.34
24-Stunden-Volumen:
560.33K
Relative Volume:
0.43
Marktkapitalisierung:
$1.09B
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-231.96M
KGV:
-4.1296
EPS:
-3.1632
Netto-Cashflow:
$-243.39M
1W Leistung:
+10.36%
1M Leistung:
-16.96%
6M Leistung:
-3.98%
1J Leistung:
+183.69%
1-Tages-Spanne:
$12.78
$13.35
1-Wochen-Bereich:
$12.14
$13.69
52-Wochen-Spanne:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.06 | 1.12B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.90 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.75 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
Chardan raises EyePoint stock price target to $29 on cash position - investing.com
EyePoint, Inc. (EYPT) stock price, news, quote and history - Yahoo Finance UK
Parkman Healthcare Partners LLC's EyePoint Inc(EYPT) Holding History - gurufocus.com
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - investing.com
Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - gurufocus.com
STU:PV3B PB Ratio: 3.51 — 21% Below Median - gurufocus.com
EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - capital.com
EyePoint Inc : Jefferies Assumes Coverage Wit - Moomoo
Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily
Stock List: Research Stocks from Around the World - gurufocus.com
Tech Rally: What is the PEG ratio of EyePoint Pharmaceuticals Inc2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus
EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - ca.investing.com
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Yahoo Finance
EYPT: DURAVYU phase III trials show strong progress, safety, and reduced treatment burden, with key data due soon - TradingView
EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN
[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - fiercepharma.com
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint sues Ocular over claims related to lead asset - MSN
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - gurufocus.com
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus - Yahoo Finance
Eyepoint files complaint against Ocular Therapeutix in Middlesex County Superior Court - marketscreener.com
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance - Sahm
Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union
EyePoint Pharmaceuticals Q4 2025 earnings preview - msn.com
Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock By Investing.com - Investing.com Australia
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - AOL.com
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock - MarketBeat
Eyepoint (EYPT) CEO Duker buys $19,723 in company stock - Investing.com
Family trust of EyePoint (EYPT) CEO acquires 1,500 company shares - Stock Titan
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus - TipRanks
Guggenheim reiterates EyePoint stock rating on Duravyu safety data By Investing.com - Investing.com Canada
Guggenheim reiterates EyePoint stock rating on Duravyu safety data - Investing.com
Finanzdaten der Eyepoint Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eyepoint Inc-Aktie (EYPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | Chief Medical Officer |
Mar 04 '26 |
Option Exercise |
8.26 |
2,438 |
20,138 |
2,438 |
| Ribeiro Ramiro | Chief Medical Officer |
Mar 04 '26 |
Sale |
17.87 |
2,438 |
43,572 |
0 |
| Ribeiro Ramiro | Chief Medical Officer |
Feb 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Feb 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
| Lurker Nancy | Director |
Jan 06 '26 |
Option Exercise |
0.00 |
75,133 |
0 |
294,346 |
| Duker Jay S. | President and CEO |
Jan 06 '26 |
Option Exercise |
0.00 |
20,793 |
0 |
87,806 |
| Elston George | Chief Financial Officer |
Jan 06 '26 |
Option Exercise |
0.00 |
15,285 |
0 |
96,339 |
| Ribeiro Ramiro | Chief Medical Officer |
Jan 05 '26 |
Option Exercise |
8.26 |
29,250 |
241,605 |
42,544 |
| Ribeiro Ramiro | Chief Medical Officer |
Jan 05 '26 |
Sale |
17.10 |
42,544 |
727,319 |
0 |
| Ribeiro Ramiro | Chief Medical Officer |
Jan 03 '26 |
Option Exercise |
0.00 |
19,667 |
0 |
19,667 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):